Marksans Pharma (NSE:MARKSANS) EPS (Basic) : ₹7.07 (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma EPS (Basic)?

Marksans Pharma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was ₹1.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.07.

Marksans Pharma's EPS (Diluted) for the three months ended in Dec. 2023 was ₹1.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.07.

Marksans Pharma's EPS without NRI for the three months ended in Dec. 2023 was ₹1.84. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 7.07.

During the past 12 months, Marksans Pharma's average EPS without NRIGrowth Rate was 35.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 32.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 49.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Marksans Pharma's highest 3-Year average EPS without NRI Growth Rate was 138.30% per year. The lowest was -182.70% per year. And the median was 17.30% per year.

Marksans Pharma EPS (Basic) Historical Data

The historical data trend for Marksans Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma EPS (Basic) Chart

Marksans Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EPS (Basic)

Get a 7-Day Free Trial

1.87

2.95

5.83

4.51

6.41

Marksans Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															1.56	1.87	1.52	1.84	1.84

Marksans Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Marksans Pharma's Basic EPS for the fiscal year that ended in Mar. 2023 is calculated as

Basic EPS (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(2663.08	-	0)	/	415.400
	=	6.41

Marksans Pharma's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(832.35	-	0)	/	452.364
	=	1.84

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7.07

Marksans Pharma (NSE:MARKSANS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Marksans Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Marksans Pharma (NSE:MARKSANS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

524404:India

Address

Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053

Website

http://www.marksanspharma.com

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines